Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Roxburgh · SciRah

Researcher profile · Semantic Scholar

P. Roxburgh

Share profile

P. Roxburgh — researcher profile on SciRah

h-index: 9
Works: 24
Citations: 466

Most-cited papers

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
M. Lolkema, H. Arkenau, K. Harrington, P. Roxburgh +8 more
2010Clinical Cancer Research130 citations Open access
Semantic Scholar
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew, B. Kaufman, Susana Banerjee, A. Lortholary +14 more
2019Annals of Oncology90 citations Open access
Semantic Scholar
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
R. Wilson, T. J. Evans, M. Middleton, L. Molife +7 more
2017British Journal of Cancer73 citations Open access
Semantic Scholar
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
V. Moreno, M. Barretina-Ginesta, J. García-Donas, G. Jayson +8 more
2021Journal for ImmunoTherapy of Cancer47 citations Open access
Semantic Scholar
Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
E. Felip, B. Doger, M. Majem, E. Carcereny +7 more
202018 citations Open access
Semantic Scholar
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
U. Banerji, E. Plummer, V. Moreno, J. Ang +16 more
2019Journal of Clinical Oncology18 citations
Semantic Scholar
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
M. Krebs, Martin Forster, M. Majem, J. Peguero +9 more
2024JTO Clinical and Research Reports14 citations Open access
Semantic Scholar
A phase I study of oral rucaparib in combination with carboplatin.
L. Molife, P. Roxburgh, R. Wilson, Avinash Gupta +15 more
201313 citations Open access
Semantic Scholar
A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
J. Peguero, P. Bajaj, E. Carcereny, T. Clay +7 more
2019Journal of Clinical Oncology10 citations
Semantic Scholar
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
M. Någård, M. Ah-See, Karen So, M. Vermunt +9 more
2020Cancer Chemotherapy and Pharmacology8 citations Open access
Semantic Scholar
A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours.
U. Banerji, N. Cook, T. R. Jeffry Evans, I. M. Candilejo +13 more
20188 citations Open access
Semantic Scholar
927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
M. Forster, E. Felip, B. Doger, A. L. Pousa +6 more
20207 citations Open access
Semantic Scholar
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
W. Cross, Iben Lyskjær, Christopher Davies, A. Bunkum +242 more
2025Genome Biology6 citations Open access
Semantic Scholar
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
J. Kurtz, V. Gebski, V. Sukhin, M. Carey +25 more
2021Gynecologic Oncology5 citations Open access
Semantic Scholar
A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.
P. Gallagher, V. Coyle, T. R. Jeffry Evans, E. Plummer +14 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
I. Braña, M. Forster, A. López-Pousa, B. Doger +7 more
20214 citations
Semantic Scholar
790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
M. Krebs, M. Majem, E. Felip, M. Forster +10 more
20204 citations Open access
Semantic Scholar
Abstract CT027: Safety, pharmacokinetics (PK) & pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)/prednisolone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC)
P. Roxburgh, D. Currie, P. Morrison, Caroline A. Kelly +8 more
2018Clinical Trials2 citations
Semantic Scholar
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer
P. Roxburgh, G. Lumsden, J. Paul, S. Harden +6 more
2014Cancer Chemotherapy and Pharmacology2 citations
Semantic Scholar
359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)
A. L. Pousa, E. Felip, M. Forster, B. Doger +7 more
2021Journal for ImmunoTherapy of Cancer1 citations Open access
Semantic Scholar
Abstract CT202: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab
M. Forster, E. Felip, B. Doger, M. Majem +8 more
2020Tumor Biology1 citations
Semantic Scholar
OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
I. McNeish, V. Moreno, G. Jayson, P. Roxburgh +9 more
2019Annals of Oncology0 citations Open access
Semantic Scholar
A phase 1 study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumors.
R. Wilson, T. Evans, M. Middleton, L. Molife +7 more
20170 citations
Semantic Scholar
Cancer Therapy: Clinical A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
M. Lolkema, H. Arkenau, K. Harrington, P. Roxburgh +8 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Bajaj×8
Invite
P. Bajaj — researcher profile on SciRah
F. Triebel×7
Invite
F. Triebel — researcher profile on SciRah
T. R. Jeffry Evans×6
Invite
T. R. Jeffry Evans — researcher profile on SciRah
B. Doger×6
Invite
B. Doger — researcher profile on SciRah

×6

Invite

E. Carcereny — researcher profile on SciRah

Invite

M. Krebs — researcher profile on SciRah

Invite

J. Peguero — researcher profile on SciRah

Invite

M. Forster — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah

Invite

M. Majem — researcher profile on SciRah

Invite

H. Arkenau — researcher profile on SciRah

Invite

R. Morrison — researcher profile on SciRah